Role of panitumumab in the management of metastatic colorectal cancer of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 2, 2006, Pages 118-124

  Saif, Muhammad Wasif ^a   Cohenuram, Michael ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Antibiotics; Cetuximab; Epidermal growth factor; Immunomodulatory agents; Rash; Steroids

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CETIRIZINE; CETUXIMAB; CLINDAMYCIN; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYTOTOXIC AGENT; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERYTHROMYCIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; IMMUNOMODULATING AGENT; IRINOTECAN; LORATADINE; METRONIDAZOLE; OXALIPLATIN; PANITUMUMAB; PSEUDOMONIC ACID; RETINOID; STEROID; TETRACYCLINE; UNINDEXED DRUG;

ACNE; AIRWAY OBSTRUCTION; ANAPHYLAXIS; AREA UNDER THE CURVE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; INJECTION SITE REACTION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; PHOTOSENSITIVITY; PROTEIN EXPRESSION; REVIEW; SKIN CARE; SKIN MANIFESTATION; SKIN TOXICITY; URTICARIA;

EID: 33749032101     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.028     Document Type: Review

References (38)

1. Ritter CA, Arteage CL. The epidermal growth factor receptor-tyrosine kinase: promising therapeutic target in solid tumors. Semin Oncol 2003; 30:3-11.
2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20(18 suppl):1s-13s.
3. Bonner JA, Harari, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 2006; 354:567-578.
4. Saltz L, Meropol N, Loehrer PJ, et al. Phase II Trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
6. Van Laethem JL, Raoul JL, Mitry E, et al. Cetuximab in combination with biweekly irinotecan, infusional 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer expressing the epidermal growth factor receptor. Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003; 22:264 (Abstract #1058).
7. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-914.
8. Khazaeli MB, LoBuglio AF, Falcey JW, et al. Low immunogenicity of a chimeric monoclonal antibody (MAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proc Am Soc Clin Oncol 2000; 19:207a (Abstract #808).
9. Yang XD, Xiao-Chi J, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer chemotherapy. Crit Rev Oncol Hematol 2001; 38:17-23.
10. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002; 29(suppl 4):47-50.
11. Yang XD, Wang P, Fredlin P, et al. ABX-EGF, a fully human anti-EGF receptor monoclonal antibody: inhibition of prostate cancer in vitro and in vivo. Proc Am Soc Clin Oncol 2002; 21:160b (Abstract #2454).
12. Wang P, Fredlin P, Davis CG, et al. Therapeutic potential of ABX-EGF, fully human anti-EGF receptor monoclonal antibody, for the treatment of renal cell carcinoma. Proc Am Soc Clin Oncol 2002; 21:191a (Abstract #761).
13. Schwartz G, Dutcher JP, Vogelzang NJ, et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 2002; 21:24a (Abstract #91).
14. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21:10a (Abstract #35).
15. Hecht R, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3511).
16. Crawford J, Sandler AB, Hammond LA, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:634 (Abstract #7083).
17. Rowinsky E, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-3015.
18. Weiner LM, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy in patients with advanced solid malignancies. J Clin Oncol 2005; 23(16 suppl):206s (Abstract #3059).
19. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(16 suppl):251s (Abstract #3520).
20. Hecht JR, Berlin J, Malik I, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leukovorin (IFL) in metastatic colorectal patients: a pharmacokinetic analysis. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hotlywood, FL. Abstract #259.
21. Berlin J, Malik I, Picus J. Panitumumab therapy with irinotecan, 5-fluorouracil, and leukovorin (IFL) in metastatic colorectal patients. Ann Oncol 2004; 15(suppl 3):iii70 (Abstract #265PD).
22. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs. BSC alone in patients with metastatic colorectal cancer. Presented at the 97th Annual Meeting of the American Association of Cancer Research, April 1-5, 2006; Washington, DC. Abstract #CP-1.
23. PACCE: a randomized, open-label, controlled, clinical trial of chemotherapy and bevacizumab with and without Panitumumab in the first-line treatment of subjects with metastatic colorectal cancer. National Cancer Institute Web site. Available at: www.clinicaltrials. gov.ct/show/NCT00115765. Accessed May 6, 2006.
24. An open-label, dose-finding study to evaluate the safety of AMG 706 plus panitumumab plus chemotherapy in the treatment of subjects with metastatic colorectal cancer. National Cancer Institute Web site. Available at: www.clinicaltrials.gov.ct/show/NCT00115765. Accessed May 6, 2006.
25. Hecht J, Mitchell E, Barada J, et al. Panitumumab antitumor activity inpatients with metastatic colorectal cancer expressing low (1-9%) or negative levels of EGFR. J Clin Oncol 2006; 24(18 suppl):157s (Abstract #3547).
26. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients with metastatic colorectal cancer expressing greater than 10% EGFR. J Clin Oncol 2006; 24(18 suppl):158s (Abstract #3548).
27. Arends R, Yang B. Flexible dosing schedules of panintimumab (ABX-EGF) in cancer patients. J Clin Oncol 2005; 25(16 suppl):214s (Abstract #3089).
28. Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with irinotecan, 5-fluorouracil, and leukovorin (IFL) or FOLFIRI for first-fine treatment of metastatic colorectal cancer. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, CA. Abstract #237.
29. Erbitux® (cetuximab) [package insert]. New York, NY: ImClone Systems Incorporated, and Princeton, NJ: Bristol-Myers Squibb Company; August 2005.
30. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-1224.
31. Herbst RS, Lorusso PM, Purdom M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4:366-369.
32. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345-356.
33. Moss JE, Burtness B. Cetuximab-associated acneiform eruption. N Engl J Med 2005; 353:e17.
34. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238-241.
35. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23:165-174.
36. Sipples R. Common side effects of anti-EGFR therapy: acneform. rash. Semin Oncol Nurs 2006; 22(1 suppl 1):28-34.
37. Rhee J, Oishi K, Garey J, et al. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin Colorectal Cancer 2005; 5(suppl 2):S101-S106.
38. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601.